U.S. Markets closed

23andMe Holding Co. (ME)

NasdaqCM - NasdaqCM Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
0.3964-0.0156 (-3.79%)
Al cierre: 04:00PM EDT
0.3860 -0.01 (-2.62%)
Fuera de horario: 07:59PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300
https://www.23andme.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo560

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Ms. Anne WojcickiCo-Founder, CEO, President & Chair of the Board62.92kN/DN/D
Mr. Joseph SelsavageChief Financial & Accounting Officer574.56kN/D1964
Mr. Eli FryVice President of OperationsN/DN/DN/D
Mr. Guy ChayounVP, Interim General Counsel & Corporate SecretaryN/DN/DN/D
Ms. Katie WatsonVice President of CommunicationsN/DN/D1978
Mr. Jonathan WardChief Marketing OfficerN/DN/DN/D
Mr. Reza Afkhami M.B.A.Chief Corporate Development OfficerN/DN/DN/D
Ms. Savita PillaiVice President of PeopleN/DN/DN/D
Dr. Jennifer Low M.D., Ph.D.Head of Therapeutics DevelopmentN/DN/D1969
Mr. Kent HillyerVice President of Consumer OperationsN/DN/D1968
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de 23andMe Holding Co. a partir del 1 de junio de 2024 es 10. Las puntuaciones principales son Auditoría: 3; Junta: 8; Derechos del accionista: 10; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.